Benign Prostatic Hyperplasia & Lower Urinary Tract Symptoms

Benign prostatic hyperplasia, the gradual enlargement of the prostate gland that affects most men as they age, is one of the most common causes of lower urinary tract symptoms. The prostate sits just below the bladder and wraps around the urethra, so when the tissue grows, it can squeeze the urinary channel and interfere with how the bladder empties and stores urine. The connection between gland size and symptom severity is not as straightforward as it sounds, though, and understanding why helps explain the wide range of treatments available today.

Why the Prostate Keeps Growing

Prostate growth is driven largely by dihydrotestosterone (DHT), a potent form of testosterone produced inside the prostate itself by an enzyme called 5-alpha reductase. DHT acts on the prostate in two ways: it stimulates the supportive (stromal) tissue to multiply, and it pushes the glandular (epithelial) tissue toward maturation.¹ Recent research has shown that when stromal cells overexpress the enzyme that makes DHT, they activate growth-signaling pathways that not only make the stromal cells proliferate faster but also send chemical signals that push neighboring epithelial cells to grow through a kind of cross-talk between cell types.²

Hormones alone do not tell the full story. Chronic inflammation inside the prostate is increasingly recognized as a co-driver of BPH. Shifts in the balance between androgens and estrogens, particularly as men age and testosterone levels dip, appear to create a microenvironment that favors ongoing low-grade inflammation.³ Immune cells called macrophages, activated within the prostate, release inflammatory signals like TNF-alpha, which in turn promote stromal cell proliferation in a self-reinforcing loop.⁴ Newer research also points to oxidative stress, a form of cellular damage from reactive molecules, and disrupted autophagy, the cell’s internal recycling system, as additional factors that may contribute to unchecked prostate growth.⁵

How Symptoms Actually Feel

Lower urinary tract symptoms linked to BPH fall into two broad camps: problems with storing urine and problems with emptying it. Storage symptoms include needing to urinate frequently during the day, feeling a sudden urgent need to go, and waking up multiple times at night to urinate (nocturia). Voiding symptoms include a weak or interrupted stream, straining to start, dribbling at the end, and the sensation that the bladder has not fully emptied.

Most men experience a mix of both. Clinicians use the International Prostate Symptom Score (IPSS), a seven-question survey, to gauge severity. One way to tease apart the two symptom types is to compare the voiding subscore with the storage subscore. In a study of men with confirmed urinary tract problems, when the voiding-to-storage ratio was above 1, about four out of five had an obstruction-type problem like BPH. When the ratio fell to 1 or below, roughly three out of four had a storage-type issue like an overactive bladder.⁶ That distinction matters because the treatments are different.

Size Is Not Everything

One of the most persistent misconceptions about BPH is that a bigger prostate automatically means worse symptoms. In reality, the correlation between prostate volume and symptom severity is weak. A man with a modestly enlarged gland can be miserable, while another with a significantly larger prostate may barely notice any urinary trouble. What matters more is where the growth happens: tissue that expands inward toward the urethra causes more obstruction than tissue that grows outward.

That said, prostate size does predict something useful. Larger prostates tend to keep growing and are more likely to lead to complications like acute urinary retention down the road. Blood levels of prostate-specific antigen (PSA) track reasonably well with prostate volume and predict future growth, which helps doctors decide whether to start a medication that shrinks the gland or simply monitor symptoms.⁷ In other words, size is less about how you feel now and more about what might happen later.

What Happens to the Bladder Over Time

When the prostate obstructs flow for months or years, the bladder does not just sit there passively. It remodels itself. The muscle wall thickens as bladder muscle cells enlarge, sometimes tripling in cross-sectional area compared to normal.⁸ Early on, this compensates: the bladder pushes harder to overcome the blockage, and voiding stays mostly normal. But if the obstruction persists, the bladder can decompensate, losing its ability to contract effectively. At that point, men develop high bladder pressures, large amounts of leftover urine after voiding, and sometimes an inability to urinate at all.

Researchers have also identified a stretch-sensing protein called PIEZO2 that may play a role in how the bladder senses fullness and responds to obstruction. In men with bladder outlet obstruction from BPH, PIEZO2 levels in bladder tissue appear to be reduced, and that reduction is linked to decreased bladder compliance and urinary retention.⁹ This is still early-stage research, but it suggests that obstruction does not just cause mechanical changes. It alters the molecular machinery that tells the bladder when and how to squeeze.

First-Line Medications

For most men with bothersome symptoms, medication is the starting point. Two drug classes form the backbone of treatment:

Alpha blockers (tamsulosin, alfuzosin, doxazosin, terazosin) relax smooth muscle in the prostate and bladder neck, easing the squeeze on the urethra. They work within days to weeks and are effective regardless of prostate size.¹⁰ Symptom scores drop and urine flow improves modestly, though you can expect the peak flow rate to increase by roughly 1.5 to 2 mL per second on average.¹¹ The most common side effects are dizziness, nasal congestion, and retrograde ejaculation, where semen goes backward into the bladder during orgasm rather than out.
5-alpha reductase inhibitors (finasteride, dutasteride) block the conversion of testosterone to DHT, actually shrinking the prostate over several months. They take longer to work but offer something alpha blockers cannot: a reduction in the risk of acute urinary retention and the eventual need for surgery.¹² Side effects can include decreased libido and erectile difficulty.

The landmark MTOPS trial showed that combining an alpha blocker with a 5-alpha reductase inhibitor cut the risk of disease progression by about two-thirds compared to placebo, significantly outperforming either drug alone.¹² Combination therapy is generally reserved for men with larger prostates and moderate-to-severe symptoms, where the long-term benefits of shrinking the gland justify adding a second medication. Long-term combination treatment appears especially helpful for men whose storage symptoms, the urgency and frequency, are most prominent at baseline.¹³

Tadalafil for Urinary Symptoms

A daily low dose of tadalafil, the same drug used for erectile dysfunction, is now approved for BPH-related symptoms. A meta-analysis found that 5 mg daily significantly improved symptom scores and quality of life over 12 weeks compared to placebo.¹⁴ This makes it a natural fit for men who have both urinary trouble and erectile dysfunction, since it addresses both with one pill.

There is an important caveat, though. While tadalafil reliably improves how symptoms feel on questionnaires, most studies have not shown a meaningful improvement in objective measures like maximum urine flow rate or post-void residual volume.¹⁵ In other words, tadalafil seems to make the symptoms bother you less rather than physically removing the obstruction. That disconnect between subjective improvement and unchanged flow rates is worth understanding if you are considering your options. The benefit holds regardless of whether you also have erectile dysfunction, but the drug does not shrink the prostate, so it is not expected to reduce the long-term risk of retention or surgery the way a 5-alpha reductase inhibitor can.

Minimally Invasive Office Procedures

For men who want more relief than pills provide but are not ready for full surgery, two office-based procedures have gained popularity: Rezūm (water vapor thermal therapy) and UroLift (prostatic urethral lift). Both can be done under local anesthesia, typically without a hospital stay, and both aim to preserve sexual function, which is a meaningful selling point for many men.

Head-to-head comparisons suggest Rezūm delivers somewhat better symptom improvement. In one study, Rezūm-treated patients reported about a 58 percent improvement in symptom scores on average, compared to roughly 45 percent for UroLift.¹⁶ Durability also differs. A multicenter analysis found that the reintervention rate for Rezūm was about 7 percent at five years, while UroLift’s was closer to 11 percent, a statistically significant difference at the three- and five-year marks.¹⁷ Both rates are far from zero, so men choosing either procedure should know that some will eventually need a repeat treatment or an escalation to surgery.

Surgery for Larger or Refractory Prostates

When medications fail or symptoms are severe, surgical removal of obstructing prostate tissue remains the most durable solution. The traditional gold standard, transurethral resection of the prostate (TURP), involves inserting a scope through the urethra and shaving away tissue. It is effective and familiar to most urologists. But a newer laser-based approach, holmium laser enucleation (HoLEP), has been steadily gaining ground.

In randomized trials, HoLEP consistently removes more tissue, leads to less blood loss, requires shorter hospital stays, and produces better improvements in peak urine flow and symptom scores compared to TURP.¹⁸ These advantages hold even for men over 75 and those with prostates larger than 60 grams, where TURP historically struggles.¹⁹ The main drawback of HoLEP is a steep learning curve for surgeons and a longer operative time. Temporary discomfort while urinating after the procedure is also more common. Still, as more urologists gain experience, HoLEP is widely expected to overtake TURP as the default surgical option.²⁰

Prostate Artery Embolization

A less conventional option sits outside the urologist’s office entirely. Prostate artery embolization (PAE) is performed by an interventional radiologist, who threads a catheter through the groin or wrist into the tiny arteries feeding the prostate and injects microscopic beads to cut off blood supply. The prostate gradually shrinks over weeks. PAE is attractive for men who are poor surgical candidates, who prefer a nonsurgical route, or who place a high priority on preserving sexual function.²¹ Recovery is typically faster than with TURP or HoLEP. However, the evidence base is still smaller than for surgical options, and long-term head-to-head trials are ongoing. PAE tends to produce more modest improvements in flow rate compared to surgery, so it is generally positioned as an alternative rather than a replacement for standard procedures.

Acute Urinary Retention

The most feared acute complication of BPH is the sudden, complete inability to urinate. Acute urinary retention (AUR) is painful and requires emergency catheterization. It can be triggered by cold medications containing decongestants or antihistamines, anesthesia after surgery, excessive alcohol, or simply the gradual worsening of obstruction over time. In a large single-center analysis of over 2,000 men presenting with a first episode of AUR, the standard protocol was to place a catheter and start an alpha blocker, then attempt a “trial without catheter” a few days later to see if the patient could void on their own.²² Some men recover enough to manage with medication going forward, while others end up needing surgery.

Nocturia, Sleep, and Falls

Among all BPH-related symptoms, nocturia tends to bother men the most. Waking up two, three, or four times a night to urinate fragments sleep in a way that compounds over months and years. The consequences go beyond fatigue. A meta-analysis found that nocturia raises the risk of falls, with the effect being more pronounced in older adults.²³ The mechanism is straightforward: navigating a dark hallway while half-asleep multiple times a night is risky, especially for men with reduced balance or mobility. Sleep deprivation also causes daytime drowsiness, which contributes to falls during waking hours. Fragmented sleep is additionally linked to depressed mood, impaired concentration, and reduced quality of life, making nocturia a symptom that affects far more than just the urinary tract.²⁴

Exercise and Metabolic Health

Physical activity appears to offer some protection against BPH and its symptoms, though the evidence is not as clean as you might hope. A recent review of 19 studies found that moderate-intensity exercise seemed more protective than high-intensity exercise, while physical activity in general showed a somewhat inconsistent but broadly positive trend. Of 14 studies looking at overall physical activity levels, half found a protective effect, while five showed no significant link.²⁵

The metabolic connection is worth understanding. Conditions like obesity, insulin resistance, and elevated blood lipids, the cluster known as metabolic syndrome, appear to amplify prostate growth and worsen urinary symptoms. Sustained physical activity reduces the overall risk of BPH and LUTS, and lifestyle changes targeting blood sugar and triglycerides may also help.²⁶ None of this means exercise is a substitute for medication in a man with significant symptoms, but it is one of the few modifiable risk factors, and it carries no downside.

Saw Palmetto and Herbal Supplements

Saw palmetto extract is by far the most widely used herbal remedy for BPH. Millions of men take it, and its proposed mechanisms overlap with prescription drugs: it may inhibit the same enzyme (5-alpha reductase) that finasteride targets and may reduce prostatic inflammation.²⁷ The evidence, however, is messy. Results vary widely depending on the formulation.

The most consistent positive results come from hexanic (fatty acid-based) extracts. A systematic review and meta-analysis of one such formulation found it reduced nighttime voiding by about 0.6 fewer trips to the bathroom compared to placebo and improved urine flow rates, with overall symptom improvement roughly comparable to tamsulosin or short-term use of a 5-alpha reductase inhibitor.²⁸ The safety profile was favorable, with mostly mild gastrointestinal side effects and, importantly, fewer sexual side effects than conventional drugs. A more recent systematic review reached a similar conclusion: benefit signals are stronger with standardized hexanic or beta-sitosterol-enriched preparations, and combination with alpha blockers may amplify the effect.²⁹

The practical takeaway is that not all saw palmetto supplements are the same. The over-the-counter capsules at a typical pharmacy are not necessarily the same formulation that performed well in trials. If you want to try it, look for a product that specifies a hexanic lipidosterolic extract with a high free fatty acid content. And keep expectations realistic: even the best results put it roughly on par with an alpha blocker for symptom relief, not dramatically better.

Voiding Position

An oddly practical question that rarely comes up in doctor’s offices: does it matter whether you stand or sit to urinate? For healthy men, it makes little difference. But for men with BPH, the answer is less intuitive than you might expect. One study found that BPH patients who stood had significantly higher maximum flow rates and lower post-void residual urine volumes compared to sitting. Residual urine was about 52 mL when standing versus 86 mL when sitting.³⁰ This is a single study, and it runs counter to some earlier research suggesting sitting might help by relaxing the pelvic floor. The takeaway is not that you must stand, but that voiding position is a variable worth experimenting with, especially if you consistently feel like your bladder is not emptying fully.

BPH Is Not a Human Exclusive

If you have an intact male dog, he is almost certainly going to develop the same condition. BPH prevalence in dogs reaches about 80 percent by age six and 95 percent by age nine.³¹ In dogs, symptoms tend to involve straining to defecate (because the prostate pushes on the rectum) more than urinary trouble, and prostate size does not correlate well with symptom severity, echoing the same disconnect seen in humans. The straightforward fix in veterinary medicine is neutering, which removes the hormonal driver. That parallel underscores how central androgens are to the condition across species and, indirectly, why 5-alpha reductase inhibitors work in men: both interventions cut off the hormonal fuel supply.